logo-loader
viewOncimmune

Oncimmune Hldngs PLC - Authorisation for EarlyCDT Lung in Brazil

RNS Number : 6213R
Oncimmune Holdings PLC
01 July 2020
 

1 July 2020

 

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

 

ANVISA authorisation brings opportunity for EarlyCDT Lung sales in large Brazilian market

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces that its distributor in Brazil, Valentech International LLC ("Valentech"), has obtained marketing authorisation for the EarlyCDT Lung blood test for the early detection of lung cancer in Brazil from Agência Nacional de Vigilância Sanitária ("ANVISA").

 

Lung cancer is the biggest cancer killer in Brazil; 34,000 people were diagnosed with lung cancer in 2018 and almost 32,000 deaths were reported from the disease in the same year1. Brazil therefore has a high unmet need for new technologies in the earlier detection of lung cancer and presents a significant market opportunity for EarlyCDT Lung.

 

This marketing authorisation is effective immediately and enables market access for EarlyCDT Lung in one of the largest addressable markets in the world. Oncimmune signed a distribution agreement with Valentech for Brazil and Colombia in 2018.

 

Dr Adam M Hill, CEO of Oncimmune said: "Survival rates from lung cancer can be increased significantly with earlier detection of the disease. We are delighted that EarlyCDT Lung can now be made available in this large market, where the need is so great."

 

1. https://gco.iarc.fr/today/data/factsheets/populations/76-brazil-fact-sheets.pdf

 

For further information:

 

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[email protected]

 

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

+44 (0)20 3829 5000

 

finnCap (Joint Broker)

Geoff Nash, Matthew Radley, Tim Redfern

+44 (0)20 7220 0500

 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

[email protected]

+44 (0)20 3727 1000

About Oncimmune

 

Our intimate understanding of the human immune system enables us to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies.

 

The key to improving cancer survival is early detection and better selection for therapy. As a company, we are driven by our passion to improve cancer survival and give people extra time. Oncimmune's immunodiagnostic test, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis.

 

The unique combination of our core technology and understanding of the immune system, powers our ImmunoINSIGHTS service; a proprietary platform that enables life science organisations to optimise drug development and delivery, leading to more effective, targeted as well as safer treatments for patients.

 

Oncimmune was founded in 2002 and launched its platform diagnostic technology in 2009, followed by the launch of its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over 200,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled trial for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) Early detection of Cancer of the Lung ("ECLS") trial of 12,209 high-risk smokers in Scotland. This trial demonstrated that EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

 

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

 

What is EarlyCDT Lung?

 

EarlyCDT is a simple blood test that detects the elevated presence of autoantibodies generated by the body's immune system as a natural defence against cancer cells.

 

EarlyCDT Lung is the world's most thoroughly validated blood test for the detection of lung cancer and requires only a small volume of blood which can be taken using a test in the home or community setting as well as a doctor's surgery. Shown to detect lung cancer on average four years earlier compared to current standard clinical diagnosis, EarlyCDT Lung can also provide an effective assessment of cancer risk in indeterminate pulmonary nodules (IPNs).

 

For more information, visit www.oncimmune.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAURORRRUUNOUR

Quick facts: Oncimmune

Price: 139.5

Market: AIM
Market Cap: £88.6 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Oncimmune CEO says they're seeing 'significant interest' in its EarlyCDT...

Oncimmune Holdings PLC's (LON:ONC) Adam Hill tells Proactive the next 18 months are expected to create substantial revenues within the EarlyCDT lung cancer test business while the pipeline of contracts within the ImmunoINSIGHTS services business is building. In a trading update covering the...

on 5/6/20